Epigenetic inactivation of galanin eceptor 1 in head and neck cancer

Clinical Cancer Research

Volumn 14, Issue 23, 2008, Pages 7604-7613

  Misawa, Kiyoshi ^a,b   Ueda, Yo ^a,b   Kanazawa, Takeharu ^a,c   Misawa, Yuki ^a,b   Jang, Ilwhan ^a,d   Brenner, John Chadwick ^a   Ogawa, Tetsuya ^a,e   SatoruTakebayashi, ^a,b   Grenman, Reidar A ^f   Herman, James G ^g   Mineta, Hiroyuki ^b   Carey, Thomas E ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

^b HAMAMATSU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c JICHI MEDICAL UNIVERSITY   (Japan)

^d Ghil Hospital   (South Korea)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

^f TURKU UNIVERSITY HOSPITAL   (Finland)

^g JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZACITIDINE; CYCLIN D1; GALANIN RECEPTOR 1; MESSENGER RNA; PROTEIN P16; TRANSCRIPTION FACTOR; TRICHOSTATIN A; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL PROLIFERATION; CONTROLLED STUDY; CPG ISLAND; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE SILENCING; HEAD AND NECK CANCER; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; METASTASIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN METHYLATION; REAL TIME POLYMERASE CHAIN REACTION; SQUAMOUS CELL CARCINOMA; TRANSCRIPTION INITIATION; TUMOR VOLUME; DNA METHYLATION; GENETIC EPIGENESIS; GENETIC TRANSFECTION; GENETICS; HEAD AND NECK TUMOR; IMMUNOHISTOCHEMISTRY; PROMOTER REGION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

AGED; BLOTTING, WESTERN; DNA METHYLATION; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION; GENES, TUMOR SUPPRESSOR; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; LOSS OF HETEROZYGOSITY; MALE; PROMOTER REGIONS, GENETIC; RECEPTOR, GALANIN, TYPE 1; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRANSFECTION; TUMOR MARKERS, BIOLOGICAL;

EID: 59449094364     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-4673     Document Type: Article

References (48)

1. Pearlstein RP, Benninger MS, CareyTE, et al. Loss of 18q predicts poor survival of patients with squamous cell carcinoma of the head and neck. Genes Chromosomes Cancer 1998;21:333-9.
2. Takebayashi S,Ogawa T, Jung KY,et al.identification of new minimally lost regions on 18q in head and neck squamous cell carcinoma. Cancer Res 2000;60: 3397-403.
3. Taborga M, Corcoran KE, Fernandes N, Ramkissoon SH, Rameshwar P. G-coupled protein receptors and breast cancer progression: potential drug targets. Mini Rev Med Chem 2007;7:245-51.
4. Touge H, Chikumi H, Igishi T, et al. Diverse activation states of RhoA in human lung cancer cells: contribution of G protein coupled receptors. Int J Oncol 2007;30:709-15.
5. Spiegelberg BD, Hamm HE. Roles of G-protein- coupled receptor signaling in cancer biology and gene transcription. Curr Opin Genet Dev 2007;17:40-4.
6. Cheng Y, Lotan R. Molecular cloning and characterization of a novel retinoic acid-inducible gene that encodes a putative G protein-coupled receptor. J Biol Chem 1998;273:35008-15.
7. Gschwind A, Prenzel N, Ullrich A. Lysophosphatidic acid-induced squamous cell carcinoma cell proliferation and motility involves epidermal growth factor receptor signal transactivation. Cancer Res 2002;62:6329-36.
8. Henson BS, Neubig RR, Jang I, et al. Galanin receptor 1 has anti-proliferative effects in oral squamous cell carcinoma. J Biol Chem 2005;280:22564-71.
9. 3 analog EB1089 signaling on cell proliferation, differentiation, and immune system regulation. Mol Endocrinol 2002;16:1243-56.
10. Rhee CS, Sen M, Lu D, et al.Wnt and frizzled receptors as potential targets for immunotherapy in head and neck squamous cell carcinomas. Oncogene 2002;21:6598-605.
11. Thomas SM, Bhola NE, Zhang Q, et al. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Cancer Res 2006;66:11831-9.
12. Zhang Q, Thomas SM, Lui VW, et al. Phosphorylation of TNF-α converting enzyme by gastrin-releasing peptide induces amphiregulin release and EGF receptor activation. Proc Natl Acad Sci U S A 2006;103:6901-6.
13. Zhang Q,Thomas SM, Xi S, et al. SRC family kinases mediate epidermal growth factor receptor ligand cleavage, proliferation, and invasion of head and neck cancer cells. Cancer Res 2004;64:6166-73.
14. Zhang X, Hunt JL, Landsittel DP, et al. Correlation of protease-activated receptor-1 with differentiation markers in squamous cell carcinoma of the head and neck and its implication in lymph node metastasis. Clin Cancer Res 2004;10:8451-9.
15. Ogawa T, Ogawa H, UedaY, et al. Expression and mutation of galanin receptor1 in head and neck squamous cell carcinoma (HNSCC) cell lines. In: Proc AACR; 2001.p. 621.
16. Wang S, Hashemi T, Fried S, Clemmons AL, Hawes BE. Differential intracellular signaling of the GalR1 and GalR2 galanin receptor subtypes. Biochemistry 1998; 37:6711-7.
17. Branchek TA, Smith KE, Gerald C, Walker MW. Galanin receptor subtypes. Trends Pharmacol Sci 2000;21: 109-17.
18. Gundlach AL. Galanin/GALP and galanin receptors: role in central control of feeding, body weight/obesity and reproduction? Eur J Pharmacol 2002;440:255-68.
19. Bartfai T, Fisone G, Langel U. Galanin and galanin antagonists: molecular and biochemical perspectives. Trends Pharmacol Sci 1992;13:312-7.
20. Wittau N, Grosse R, Kalkbrenner F, Gohla A, Schultz G, Gudermann T. The galanin receptor type 2 initiates multiple signaling pathways in small cell lung cancer cells by coupling to G (q), G(i) and G (12) proteins. Oncogene 2000;19:4199-209.
21. Berger A, Lang R, Moritz K, et al. Galanin receptorsubtype GalR2 mediates apoptosis in SH-SY5Y neuroblastoma cells. Endocrinology 2004;145:500-7.
22. Kanazawa T, Iwashita T, Kommareddi P, et al. Galanin and galanin receptor type 1 suppress proliferation in squamous carcinoma cells: activation of the extracellular signal regulated kinase pathway and induction of cyclin-dependentkinase inhibitors. Oncogene 2007;26:5762-71.
23. Suzuki K, Suzuki I, Leodolter A, et al. Global DNA demethylation in gastrointestinal cancer is age dependentand precedes genomic damage. Cancer Cell 2006;9:199-207.
24. Iismaa TP, Fathi Z, Hort YJ, et al. Structural organization and chromosomal localization of three human galanin receptor genes. Ann N Y Acad Sci 1998; 863:56-63.
25. Baylin SB, Ohm JE. Epigenetic gene silencing in cancer-a mechanism for early oncogenic pathway addiction? Nat Rev 2006;6:107-16.
26. Verma M, Srivastava S. Epigenetics in cancer: implications for early detection and prevention. Lancet Oncol 2002;3:755-63.
27. Park NH, Min BM, Li SL, Huang MZ, Cherick HM, Doniger J. Immortalization of normal human oral keratinocytes with type 16 human papillomavirus. Carcinogenesis 1991;12:1627-31.
28. Herman JG, Graff JR, Myohanen S, Nelkin BD, Baylin SB. Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A1996;93:9821-6.
29. Kuroki T, Trapasso F, Yendamuri S, et al. Allele loss and promoter hypermethylation of VHL, RAR-β, RASSF1A, and FHIT tumor suppressor genes on chromosome 3p in esophageal squamous cell carcinoma. Cancer Res 2003;63:3724-8.
30. Berger A, Tuechler C, Almer D, et al. Elevated expression of galanin receptors in childhood neuroblastic tumors. Neuroendocrinology 2002;75:130-8.
31. MinetaH,Miura K, TakebayashiS, et al. CyclinD1 overexpression correlates with poor prognosis in patients with tongue squamous cell carcinoma. Oral Oncol 2000;36:194-8.
32. Cheung JO, Grant ME, Jones CJ, Hoyland JA, Freemont AJ, Hillarby MC. Apoptosis of terminal hypertrophic chondrocytes in an in vitro model of endochondral ossification. J Pathol 2003;201: 496-503.
33. Wada M, Yazumi S, Takaishi S, et al. Frequent loss of RUNX3 gene expression in human bile ductand pancreatic cancer cell lines. Oncogene 2004;23: 2401-7.
34. HuangY, Peng J, Oberley LW, Domann FE.Transcriptional inhibition of manganese superoxide dismutase (SOD2) gene expression by DNA methylation of the 5′ CpG island. Free Radic Biol Med 1997;23:314-20.
35. Clark SJ, Harrison J, Molloy PL. Sp1 binding is inhibited by (m)Cp(m)CpG methylation. Gene 1997; 195:67-71.
36. Van Dyke DL, Worsham MJ, Benninger MS, et al. Recurrent cytogenetic abnormalities in squamous cell carcinomas of the head and neck region. Genes Chromosomes Cancer 1994;9:192-206.
37. Takebayashi S, Hickson A, Ogawa T, et al. Loss of chromosome arm 18q with tumor progression in head and neck squamous cancer. Genes Chromosomes Cancer 2004;41:145-54.
38. Gutkind JS. Cell growth control by G protein- coupled receptors: from signal transduction to signal integration. Oncogene 1998;17:1331-42.
39. Dote H, Toyooka S, Tsukuda K, et al. Aberrant promoter methylation in human DAB2 interactive protein (hDAB2IP) gene in breastcancer. Clin Cancer Res 2004;10:2082-9.
40. Toyooka S, Toyooka KO, Harada K, et al. Aberrant methylation of the CDH13 (H-cadherin) promoter region in colorectal cancers and adenomas. Cancer Res 2002;62:3382-6.
41. WilliamsT, Tjian R. Analysis of the DNA-binding and activation properties of thehuman transcription factor AP-2. Genes Dev 1991;5:670-82.
42. Tellez C, Bar-Eli M. Role and regulation of the thrombin receptor (PAR-1) in human melanoma. Oncogene 2003;22:3130-7.
43. Xu Y, Porntadavity S, St Clair DK. Transcriptional regulation of the human manganese superoxide dismutase gene: the role of specificity protein 1 (Sp1) and activating protein-2 (AP-2). Biochem J 2002; 362:401-12.
44. Comb M, Goodman HM. CpG methylation inhibits proenkephalin gene expression and binding of the transcription factor AP-2. Nucleic Acids Res 1990;18: 3975-82.
45. Zou MX, Butcher DT, Sadikovic B, GrovesTC, Yee SP, Rodenhiser DI. Characterization of functional elements in the neurofibromatosis (NF1) proximal promoter region. Oncogene 2004;23:330-9.
46. Mancini DN, Singh SM, ArcherTK, Rodenhiser DI. Site-specific DNA methylation in the neurofibromatosis (NF1) promoter interferes with binding of CREB and SP1 transcription factors. Oncogene 1999; 18: 4108-19.
47. Fujita N, WatanabeS, Ichimura T, et al.MCAF mediates MBD1-dependent transcriptional repression. Mol Cell Biol 2003;23:2834-43.
48. Nakao M. Epigenetics: interaction of DNA methylation and chromatin. Gene 2001;278:25-31.